Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TLC-2716
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
Details : TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 11, 2022
Lead Product(s) : TLC-2716
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : OrsoBio
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Px-104
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2013
Lead Product(s) : Px-104
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PX-102
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Ascending Oral Dose Phase I Study With Px-102
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2013
Lead Product(s) : PX-102
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PX-102
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Oral Dose Phase I Study With Px-102
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2013
Lead Product(s) : PX-102
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
